Skip to main content Accessibility help
×
Home
Hostname: page-component-857cdc78dc-d29nz Total loading time: 0.534 Render date: 2022-05-16T06:33:50.476Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

1 - Introduction

Published online by Cambridge University Press:  18 December 2009

Frank A. Sloan
Affiliation:
Professor of Health Policy and Management and Professor of Economics, Duke University
Chee-Ruey Hsieh
Affiliation:
Research Fellow in the Institute of Economics at Academia Sinica, Taipei, Taiwan, Vanderbilt University
Frank A. Sloan
Affiliation:
Duke University, North Carolina
Chee-Ruey Hsieh
Affiliation:
Academia Sinica, Taipei, Taiwan
Get access

Summary

Context

The pharmaceutical industry serves a dual role in modern society. On one hand, it is a growing industry, and its output makes a direct contribution to gross domestic product (GDP). On the other, prescription drugs, this industry's major output, are an input in the production of good health. These products make an important contribution to the improvement of population health.

The purpose of this book is to investigate public policy issues in pharmaceutical innovation. In Section II we first describe the important characteristics of prescription drugs. We emphasize that these characteristics deviate from the standard conditions in a competitive market. In Section III we discuss the current performance of the pharmaceutical market. In Section IV we investigate market failures that persist in allocating research and development (R&D) resources and in the utilization of prescription drugs. In Section V we analyze the policy conflict between the economic and health sectors arising from pharmaceutical innovation. The final section discusses the structure of the book and the major content of the chapters.

Characteristics of Prescription Drugs

Prescription drugs have many complex characteristics, which, when taken together, have led to major controversies in public policy arenas, including pricing, patents, and incentives for research and development, as well as excess industry profits. Each characteristic is not unique to pharmaceuticals, but rather it is the characteristics, taken in combination, that make the industry unique.

Probabilistic Nature of Demand and Effectiveness

Prescription drugs are inputs in the production of good health.

Type
Chapter
Information
Pharmaceutical Innovation
Incentives, Competition, and Cost-Benefit Analysis in International Perspective
, pp. 1 - 22
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
4
Cited by

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Introduction
    • By Frank A. Sloan, Professor of Health Policy and Management and Professor of Economics, Duke University, Chee-Ruey Hsieh, Research Fellow in the Institute of Economics at Academia Sinica, Taipei, Taiwan, Vanderbilt University
  • Edited by Frank A. Sloan, Duke University, North Carolina, Chee-Ruey Hsieh, Academia Sinica, Taipei, Taiwan
  • Book: Pharmaceutical Innovation
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511618871.002
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Introduction
    • By Frank A. Sloan, Professor of Health Policy and Management and Professor of Economics, Duke University, Chee-Ruey Hsieh, Research Fellow in the Institute of Economics at Academia Sinica, Taipei, Taiwan, Vanderbilt University
  • Edited by Frank A. Sloan, Duke University, North Carolina, Chee-Ruey Hsieh, Academia Sinica, Taipei, Taiwan
  • Book: Pharmaceutical Innovation
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511618871.002
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Introduction
    • By Frank A. Sloan, Professor of Health Policy and Management and Professor of Economics, Duke University, Chee-Ruey Hsieh, Research Fellow in the Institute of Economics at Academia Sinica, Taipei, Taiwan, Vanderbilt University
  • Edited by Frank A. Sloan, Duke University, North Carolina, Chee-Ruey Hsieh, Academia Sinica, Taipei, Taiwan
  • Book: Pharmaceutical Innovation
  • Online publication: 18 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511618871.002
Available formats
×